The purpose of this clinical research study is to provide entecavir to subjects with chronic Hepatitis B infection who have failed or who have demonstrated intolerance of marketed therapies or for those in whom use of these agents is contraindicated and that have no other available treatment options.
Study Type
EXPANDED_ACCESS
Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
Local Institution
Jerusalem, Israel
Local Institution
Nazareth, Israel
Local Institution
Petah Tikva, Israel
Local Institution
Safed, Israel
Local Institution
Tel Aviv, Israel
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.